m-EASIX (better than EASIX) predicts severe CAR T-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsis.
Por:
Moreno-Castaño AB, Fernández S, Brillembourg H, Iraola G, Moreno DF, Ventosa-Capell H, Martinez-Sanchez J, De Moner B, Molina P, Ramos A, Palomo M, Gómez-Ramírez P, Ortiz-Maldonado V, Martínez-Cibrián N, Delgado J, Oliver-Caldés A, Fernández de Larrea C, Salas MQ, Urbano Á, Téllez A, Nicolás JM, Juan M, González-Navarro A, Penack O, Escolar G, Carreras E, Fernández-Avilés F, Castro P and Diaz-Ricart M
Publicada:
7 ene 2026
Ahead of Print:
7 ene 2026
Resumen:
BACKGROUND: Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) are life-threatening complications that often arise after CAR T-cell immunotherapy. Endothelial dysfunction is believed to play a central role in their development, leading to the interest in biomarker-based tools for diagnosis and differentiating these toxicities from sepsis. This study aimed to evaluate the Endothelial Activation Stress Index (EASIX) and its modified version (m-EASIX, which replaces creatinine with C-reactive protein [CRP] (mg/dL)) as early predictors of severe CRS and ICANS, as well as tools to distinguish CRS from sepsis. METHODS: One hundred and nineteen patients treated with CAR T-cell therapy for CD19-positive hematologic malignancies (n=94) or multiple myeloma (n=23) were included. EASIX and m-EASIX scores were measured at various time points: before CAR T-cell infusion, 24-48 hours post-infusion, at CRS or ICANS onset, and after treatment for each toxicity. A comparator group of 129 sepsis patients, including 86 with hematologic malignancies, was also analyzed. RESULTS: Both EASIX and m-EASIX correlated with biomarkers of endotheliopathy, with m-EASIX showing stronger predictive power for severe toxicities and ICU admission. Higher EASIX and m-EASIX values at early time points were associated with worse overall survival (OS). Furthermore, m-EASIX accurately distinguished CRS from sepsis at symptom onset. CONCLUSIONS: m-EASIX is a practical and accessible tool for the early prediction of severe CAR T-cell-related toxicities, risk stratification, and differential diagnosis from sepsis, offering potential to guide clinical decision-making and early intervention.
Filiaciones:
Moreno-Castaño AB:
Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre Diagnòstic Biomèdic (CDB), Clínic Barcelona, Barcelona, Spain
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Fernández S:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Medical Intensive Care Unit, Clínic Barcelona, Barcelona, Spain
Brillembourg H:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Iraola G:
Medical Intensive Care Unit, Clínic Barcelona, Barcelona, Spain
Moreno DF:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Ventosa-Capell H:
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Medical Intensive Care Unit, Clínic Barcelona, Barcelona, Spain
Martinez-Sanchez J:
Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre Diagnòstic Biomèdic (CDB), Clínic Barcelona, Barcelona, Spain
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
:
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Josep Carreras Leukaemia Research Institute (Campus Clinic), Barcelona, Spain
Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre Diagnòstic Biomèdic (CDB), Clínic Barcelona, Barcelona, Spain
Molina P:
Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre Diagnòstic Biomèdic (CDB), Clínic Barcelona, Barcelona, Spain
Ramos A:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Palomo M:
Hematology External Quality Assessment Laboratory, Centre de Diagnòstic Biomèdic, Clínic Barcelona, Barcelona, Spain
Gómez-Ramírez P:
Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre Diagnòstic Biomèdic (CDB), Clínic Barcelona, Barcelona, Spain
Ortiz-Maldonado V:
Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain
Martínez-Cibrián N:
Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain
Delgado J:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain
Oliver-Caldés A:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain
Fernández de Larrea C:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain
Salas MQ:
Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain
Urbano Á:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain
Téllez A:
Medical Intensive Care Unit, Clínic Barcelona, Barcelona, Spain
Nicolás JM:
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Medical Intensive Care Unit, Clínic Barcelona, Barcelona, Spain
Juan M:
Immunology Department, Centre de Diagnòstic Biomèdic, Clínic Barcelona, Barcelona, Spain
González-Navarro A:
Immunology Department, Centre de Diagnòstic Biomèdic, Clínic Barcelona, Barcelona, Spain
Penack O:
Charité Hospital, Berlin, Germany
Escolar G:
Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre Diagnòstic Biomèdic (CDB), Clínic Barcelona, Barcelona, Spain
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Carreras E:
Josep Carreras Leukaemia Research Institute (Campus Clinic), Barcelona, Spain
Fernández-Avilés F:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain
Castro P:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Medical Intensive Care Unit, Clínic Barcelona, Barcelona, Spain
Diaz-Ricart M:
Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre Diagnòstic Biomèdic (CDB), Clínic Barcelona, Barcelona, Spain
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Green Submitted, gold
|